10/12/15 - 04:08 PM EDT
The heady days when a biotech company cancelling investor meetings was interpreted as a good thing -- perhaps a sign of a pending takeover -- appear to be over.
10/12/15 - 09:46 AM EDT
Eli Lilly is shutting down clinical development of a cholesterol-lowering pill, removing what could have been the company's next multi-billion-dollar product from its research pipeline.
10/08/15 - 12:10 PM EDT
Advancing the new Vertex drugs into the clinic should also quiet, but not eliminate, investor concerns about competitors closing the gap on the company's market-dominant position in cystic fibrosis treatments.
10/08/15 - 08:49 AM EDT
Biogen has the opportunity to make amends for its second-quarter earnings blow-up when it reports third-quarter earnings in two weeks.
10/06/15 - 05:07 PM EDT
The FDA placed a halt on clinical trials involving a cancer immunotherapy from Advaxis because of concerns a bacteria used to deliver the drug contributed to a patient death.
10/06/15 - 10:44 AM EDT
An independent panel of health care experts did not include Exact Sciences' Cologuard on a draft list of recommended colon cancer screening tests in the U.S.
10/05/15 - 12:53 PM EDT
Using cash to settle the debt was MannKind's worst-case option because it leaves the company with little money to fund ongoing operations.
10/02/15 - 10:43 AM EDT
There's a valuable, albeit painful, lesson here in Amicus' blow-up. Biotech CEOs should shut their mouths about regulatory plans until they receive definitive word from the FDA.
10/02/15 - 06:09 AM EDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
10/01/15 - 07:05 AM EDT
Sarepta hopes the new data will convince FDA to approve eteplirsen as a new treatment for Duchenne early next year.